Every 8-K that Zai Lab Limited (ZLAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZLAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZLAB filings page.
Zai Lab Limited reported second quarter 2026 total revenue of $106.3 million, with net product revenue of $105.8 million and an 11% sequential increase versus the prior quarter. Research and development expenses rose to $61.8 million and selling, general and administrative expenses were $72.9 million. Loss from operations was $76.5 million, or $60.4 million on a non-GAAP basis excluding depreciation, amortization, and share-based compensation. Net loss was $50.8 million, or $0.05 per ordinary share and $0.46 per ADS. Cash, cash equivalents, short-term investments, and current restricted cash totaled $717.5 million as of June 30, 2026.
The company highlighted continued progress in its pipeline. Zocilurtatug pelitecan (zoci) received U.S. and EU orphan drug designations and a second FDA Fast Track Designation and is moving toward multiple registrational studies in small cell lung cancer and extrapulmonary neuroendocrine carcinomas. China’s NMPA approved TIVDAK for recurrent or metastatic cervical cancer, KarXT was commercially launched in mainland China for schizophrenia, and VYVGART’s U.S. label was expanded to all generalized myasthenia gravis serotypes. A BLA for povetacicept in IgA nephropathy was accepted with a PDUFA target action date of November 30, 2026, and management outlined several key data readouts and regulatory milestones expected through the first half of 2027.
Zai Lab Limited held its 2026 Annual General Meeting of Shareholders, where 550,281,867 ordinary shares were represented in person or by proxy. Shareholders approved all proposals, including the re-election of all nominated directors to serve until the 2027 annual meeting.
They also approved the appointment of KPMG LLP and KPMG as independent auditors for the year ending December 31, 2026, and authorized the board to set auditor compensation. On an advisory basis, shareholders approved the compensation of the named executive officers.
In addition, shareholders granted a general mandate to the board to allot and issue, or resell treasury, ordinary shares and/or ADSs of up to 10% of issued ordinary shares, and a separate mandate to repurchase up to 10% of issued ordinary shares, both effective until the 2027 annual meeting.
Zai Lab Limited reported a senior leadership change. The Board determined that Josh Smiley will cease serving as President and Chief Operating Officer effective May 18, 2026, with his last day of employment on May 22, 2026.
Responsibilities from these roles have been taken over by Board Chair, Founder and Chief Executive Officer Samantha Du and other members of the management team. Mr. Smiley will receive severance under his existing employment agreement, contingent on signing a customary release.
Zai Lab Limited reported first-quarter 2026 total revenue of $99.6 million, down 6% year over year, as weaker oncology sales offset growth in newer products. Net product revenue was $95.6 million, a 10% decline, mainly from lower ZEJULA and VYVGART sales.
ZEJULA revenue fell to $30.0 million from $49.5 million due to volume-based procurement for a competing generic, while VYVGART slipped to $17.6 million after a pricing adjustment tied to NRDL renewal. XACDURO and NUZYRA grew to $8.6 million and $16.3 million, respectively.
Research and development expenses rose to $65.6 million and SG&A to $65.1 million, leading to a GAAP operating loss of $69.4 million and net loss of $51.0 million, or $0.05 per ordinary share. Zai Lab ended March 31, 2026 with $761.3 million in cash, equivalents, short-term investments, and current restricted cash.
The company highlighted standout intracranial response data for its DLL3-targeting ADC zocilurtatug pelitecan in small cell lung cancer and epNECs, new collaborations with Amgen and Boehringer Ingelheim, advancing atopic dermatitis candidate ZL-1503, and positive Phase 3 data from partners’ programs povetacicept in IgA nephropathy and elegrobart in thyroid eye disease.
Zai Lab Limited reported strong growth for the fourth quarter and full year 2025 while narrowing losses. Total revenue reached $127.6 million in Q4 2025 and $460.2 million for the full year, up 17% and 15% year over year, driven mainly by XACDURO and NUZYRA.
Product revenue rose to $457.2 million in 2025 from $397.6 million. ZEJULA generated $189.0 million, VYVGART $94.2 million, XACDURO $22.9 million, and NUZYRA $60.8 million. Operating loss improved to $229.4 million from $282.1 million, and net loss shrank to $175.5 million from $257.1 million.
The company ended 2025 with $789.6 million in cash, cash equivalents, short-term investments, and current restricted cash. Zai Lab also highlighted major pipeline and regulatory milestones, including China approval of KarXT for schizophrenia, FDA approval of Tumor Treating Fields in pancreatic cancer, and advancing global oncology and immunology programs with multiple 2026 data readouts and potential approvals.
Zai Lab Limited filed a Form 8-K stating it furnished a press release announcing its third-quarter 2025 financial results. The press release is included as Exhibit 99.1 and is provided under Item 2.02 (Results of Operations and Financial Condition). The information is furnished and not deemed filed under the Exchange Act. The company’s ADSs, each representing 10 ordinary shares, trade on Nasdaq under ZLAB, with ordinary shares listed in Hong Kong under 9688.
Zai Lab Limited entered into a maximum amount guarantee and established a revolving credit facility to support working capital in mainland China. The company will guarantee working capital loans of up to RMB300 million (approximately $42.1 million) from Industrial Bank Co., Ltd., Shanghai Gubei Branch, to its wholly owned subsidiary, Zai Lab (Shanghai) Co., Ltd.
The RMB300 million revolving credit facility is available until May 5, 2026. Each working capital loan is expected to have a one‑year term, with specific amounts, terms, and interest rates set in loan‑level documents. The credit line includes customary representations, warranties, and covenants, including a requirement to obtain prior written consent from the lender for transactions that could adversely impact debt repayment ability, such as mergers, spin-offs, equity transfers, external investments, or substantial debt increases.
As of this report, Zai Lab Shanghai has not entered into any working capital loans under the facility.